Conference
March 18–20, 2016

Pre-Conference Courses
March 17–18, 2016

Omni Hotel San Diego
675 L Street
San Diego, CA 92101

facebook.com/nationallipid
twitter.com/nationallipid
instagram.com/nationallipid

Clinical lipid update
MARCH 18–20
2016
SAN DIEGO

Jointly hosted by PLA and MWLA

Register at lipid.org/springclu
We invite you to attend the Spring Clinical Lipid Update (CLU) taking place March 18–20, 2016, at the Omni Hotel San Diego.

Earn 29+ hours of continuing medical education when attending the CLU and additional courses and symposia. World-renowned speakers will discuss PCSK9 inhibition and the new paradigm in LDL-C reduction, debate lifestyle therapies, present updates on lipid management in special populations, and cover many other relevant topics.

Meet experts in clinical lipidology, network with colleagues, and learn about the latest developments in the field.

We look forward to seeing you in San Diego!

San Diego, CA
March 18–20, 2016

NEW IN 2016:
Mobile Meeting App
More information on page 13.

PRE-CONFERENCE COURSES

Lipid Academy
Thursday, March 17 • 8:30 AM–5:15 PM
Friday, March 18 • 9:00 AM–3:30 PM
$550 NLA Members, $950 Non-Members, $0 Trainees

Attend the pre-conference course, perfect for first-time attendees of the CLU. This interactive course provides a comprehensive, in-depth indoctrination to lipid science.

Masters in Lipidology
Thursday, March 17 • 8:00 AM–5:55 PM
Friday, March 18 • 7:30 AM–3:30 PM
$750 NLA Members, $1,250 Non-Members, $395 Trainees

Register for this pre-conference course for an in-depth review of the core curriculum in clinical lipidology. The new case-based, interactive agenda will improve your clinical decision-making skills and help prepare you for certification in clinical lipidology.

Coding Course
Friday, March 18 • 8:00 AM–12:30 PM
$200 NLA Members, $200 Non-Members, $200 Trainees

The one-day coding course Advances in Coding: Exploring ICD-10 Implementations has been designed to assist in assuring accurate coding and reimbursement by offering a variety of educational programs and coding tools. The course will provide the understanding and skills necessary to ensure the financial health to provide quality care to patients.

For more information on all pre-conference courses, visit lipid.org/springclu.

Register early and save at lipid.org/springclu.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Thursday, March 17</strong></td>
<td></td>
</tr>
<tr>
<td>7:30–8:00 AM</td>
<td>Registration – Masters in Lipidology</td>
</tr>
<tr>
<td>8:00–8:30 AM</td>
<td>Registration – Lipid Academy</td>
</tr>
<tr>
<td><strong>Friday, March 18</strong></td>
<td></td>
</tr>
<tr>
<td>7:30–8:00 AM</td>
<td>Registration – Coding Course</td>
</tr>
<tr>
<td>8:00–8:30 AM</td>
<td>Sessions Registration Hours</td>
</tr>
<tr>
<td><strong>Saturday, March 19</strong></td>
<td>Registration Hours</td>
</tr>
<tr>
<td>7:00 AM–5:00 PM</td>
<td></td>
</tr>
<tr>
<td><strong>Sunday, March 20</strong></td>
<td></td>
</tr>
<tr>
<td>7:00–10:00 AM</td>
<td>Breakfast</td>
</tr>
</tbody>
</table>

**GENERAL EDUCATION**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM–5:55 PM</td>
<td>Masters in Lipidology</td>
</tr>
<tr>
<td>8:30 AM–5:15 PM</td>
<td>Lipid Academy</td>
</tr>
<tr>
<td>9:00 AM–3:30 PM</td>
<td>Coding Course</td>
</tr>
<tr>
<td>3:40–6:00 PM</td>
<td>Session I</td>
</tr>
<tr>
<td>7:30 AM–3:30 PM</td>
<td>Masters in Lipidology</td>
</tr>
<tr>
<td>8:00 AM–12:30 PM</td>
<td>Lipid Academy</td>
</tr>
<tr>
<td>1:45–3:55 PM</td>
<td>Session I</td>
</tr>
<tr>
<td>7:50–10:00 AM</td>
<td>Session II</td>
</tr>
<tr>
<td>4:05–6:15 PM</td>
<td>Session V</td>
</tr>
</tbody>
</table>

**EXHIBIT HALL**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00–7:00 PM</td>
<td>Welcome Reception in Exhibit Hall</td>
</tr>
<tr>
<td>7:00 AM–3:00 PM</td>
<td>Exhibit Hall Hours</td>
</tr>
<tr>
<td>7:00–7:50 AM</td>
<td>Breakfast</td>
</tr>
<tr>
<td>12:45–1:45 PM</td>
<td>Lunch</td>
</tr>
</tbody>
</table>

**SPECIAL EVENTS**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00–9:30 PM</td>
<td>Satellite Symposium Slot</td>
</tr>
<tr>
<td>6:30–7:50 AM</td>
<td>Satellite Symposium Slot</td>
</tr>
<tr>
<td>6:30–7:50 AM</td>
<td>New Member Breakfast</td>
</tr>
<tr>
<td>12:50–1:40 PM</td>
<td>Expert Theater Slots</td>
</tr>
<tr>
<td>6:30–9:15 PM</td>
<td>FNLA Event</td>
</tr>
</tbody>
</table>

---

“The NLA meetings always offer the greatest breadth and depth in lipidology updates.”

— Eliot Brinton, 2015 Spring CLU attendee

“NLA activities provide timely exposure to current research, clinical management strategies, & public health issues, great speakers.”

— Lawrence Liebmann, 2015 Spring CLU attendee

“This was my first NLA conference. The NLA staff and members were so welcoming! The conference provided not only the latest best practice for lipid management but opportunities for networking and collaboration. Thank you for a wonderful experience.”

— Elizabeth Bradley, 2015 Fall CLU attendee

“I am reinvigorated to move forward with my career as a Lipidologist.”

— Morton Saunders, 2015 Fall CLU attendee

“Superb. – I will cross the Atlantic Ocean again – to join an NLA activity!”

— Ib Christian Klausen, 2015 Fall CLU attendee
### Friday, March 18, 2016

**Session I: PCSK9 Inhibition: A New Paradigm in LDL-C Reduction**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:40–3:50 PM</td>
<td>Chapter Presidents Welcome &amp; Introduction</td>
<td></td>
</tr>
<tr>
<td>3:50–4:00 PM</td>
<td>ARS Questions</td>
<td></td>
</tr>
<tr>
<td>4:00–4:30 PM</td>
<td>PCSK9 Inhibitors: Do the FDA-Approved Indications Mandate Lipid Goals?</td>
<td>Jane F. Barlow, MD, MPH, MBA</td>
</tr>
<tr>
<td>4:30–5:00 PM</td>
<td>PCSK9 Inhibitors: Impact on the Management of LDL Apheresis Candidates and LDL Apheresis Patients</td>
<td>Anne C. Goldberg, MD, FNLA*</td>
</tr>
<tr>
<td>5:00–5:30 PM</td>
<td>PCSK9 Inhibitors: Should They Be Used in Statin Intolerant Patients?</td>
<td>Terry A. Jacobson, MD, FNLA*</td>
</tr>
<tr>
<td>5:30–6:00 PM</td>
<td>ARS Questions and Q&amp;A Panel</td>
<td></td>
</tr>
<tr>
<td>6:00–7:00 PM</td>
<td>Welcome Reception in Exhibit Hall</td>
<td></td>
</tr>
</tbody>
</table>

### Saturday, March 19, 2016

**Session II: Keeping Up to Date in Clinical Lipidology**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00–7:50 AM</td>
<td>Breakfast in Exhibit Hall</td>
<td></td>
</tr>
<tr>
<td>7:50–8:00 AM</td>
<td>Housekeeping Notes &amp; ARS Questions for Session II</td>
<td>Seth S. Martin, MD, MHS, FACC</td>
</tr>
<tr>
<td>8:00–8:30 AM</td>
<td>Using Big Data: The Very Large Database of Lipids</td>
<td>Kevin C. Maki, PhD, CLS, FNLA</td>
</tr>
<tr>
<td>8:30–9:00 AM</td>
<td>Key Clinical Lipidology Articles in 2015-2016</td>
<td></td>
</tr>
<tr>
<td>9:00–9:30 AM</td>
<td>Key Clinical Lipidology Research in Progress in 2016</td>
<td>Harold E. Bays, MD, FNLA*</td>
</tr>
<tr>
<td>9:30–10:00 AM</td>
<td>ARS Questions and Q&amp;A Panel</td>
<td></td>
</tr>
<tr>
<td>10:00–10:20 AM</td>
<td>Break in Exhibit Hall</td>
<td></td>
</tr>
</tbody>
</table>

**Session III: Application of Innovative Diagnostic Techniques to the Practice of Clinical Lipidology**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:20–10:30 AM</td>
<td>ARS Questions</td>
<td></td>
</tr>
<tr>
<td>10:30–11:00 AM</td>
<td>Micro RNA’s as Regulators of Lipid Metabolism: What Are the Therapeutic Implications? Kathryn J. Moore, PhD</td>
<td></td>
</tr>
<tr>
<td>11:00–11:30 AM</td>
<td>What Has Intravascular Ultrasound Taught the Clinical Lipidologist?</td>
<td>Steve E. Nissen, MD, FACC</td>
</tr>
<tr>
<td>11:30 AM–12:00 PM</td>
<td>Hypertriglyceridemia: Application of Genetic Insights to Diagnosis and Management</td>
<td>Joseph L. Witztum, MD</td>
</tr>
<tr>
<td>12:00–12:30 PM</td>
<td>ARS Questions and Q&amp;A Panel</td>
<td></td>
</tr>
<tr>
<td>12:30–12:45 PM</td>
<td>NLA News &amp; Notes</td>
<td></td>
</tr>
<tr>
<td>12:45–1:45 PM</td>
<td>Lunch in Exhibit Hall</td>
<td></td>
</tr>
</tbody>
</table>
### Session IV: Debates in Lifestyle Therapy

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:45–1:55 PM</td>
<td>ARS Questions</td>
<td></td>
</tr>
<tr>
<td>1:55–2:05 PM</td>
<td>Saturated Fat and ASCVD Risk: Synthesizing the Evidence for Optimal Patient Care</td>
<td>Penny Kris-Etherton, PhD, RD, CLS, FNLA</td>
</tr>
<tr>
<td>2:05–2:15 PM</td>
<td>Saturated Fat and ASCVD Risk: Examining the Strengths and Limitations of the Evidence</td>
<td>Andrew Mente, PhD</td>
</tr>
<tr>
<td>2:15–2:25 PM</td>
<td>Rebuttal</td>
<td></td>
</tr>
<tr>
<td>2:25–2:35 PM</td>
<td>Saturated Fat is Not a Good Basis for Choosing What to Eat</td>
<td>David R. Jacobs, PhD</td>
</tr>
<tr>
<td>2:35–2:45 PM</td>
<td>All Saturated Fatty Acids Must Be Considered in the SFA Recommendations for LDL-C and Non-HDL-C Lowering</td>
<td>Kevin C. Maki, PhD, CLS, FNLA</td>
</tr>
<tr>
<td>2:45–2:55 PM</td>
<td>Rebuttal</td>
<td></td>
</tr>
<tr>
<td>2:55–3:05 PM</td>
<td>Pro: Aerobic Physical Activity Lowers LDL</td>
<td>Ralph La Forge, MSc, CLS, FNLA</td>
</tr>
<tr>
<td>3:05–3:15 PM</td>
<td>Con: Aerobic Physical Activity Lowers LDL</td>
<td>John M. Jakicic, PhD</td>
</tr>
<tr>
<td>3:15–3:25 PM</td>
<td>Rebuttal</td>
<td></td>
</tr>
<tr>
<td>3:25–3:35 PM</td>
<td>ARS Questions and Q&amp;A Panel</td>
<td></td>
</tr>
<tr>
<td>3:35–4:05 PM</td>
<td>Break</td>
<td></td>
</tr>
</tbody>
</table>

### Session V: New Advances in Treatment of Familial Hypercholesterolemia

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:05–4:15 PM</td>
<td>ARS Questions</td>
<td></td>
</tr>
<tr>
<td>4:15–4:45 PM</td>
<td>FH Is More Common than Most People Think: Prevalence Data and Practical Aspects of Genetic Testing</td>
<td>Nathan Stitziel, MD, PhD</td>
</tr>
<tr>
<td>4:45–5:15 PM</td>
<td>PCSK9 Inhibitors: Practical Aspects of Their Use in FH Patients</td>
<td>James A. Underberg, MD, MS, FNLA*</td>
</tr>
<tr>
<td>5:15–5:45 PM</td>
<td>Familial Hypercholesterolemia from the Patient Perspective</td>
<td>Linda C. Hemphill, MD, FNLA*</td>
</tr>
<tr>
<td>5:45–6:15 PM</td>
<td>ARS Questions and Q&amp;A Panel</td>
<td></td>
</tr>
<tr>
<td>6:30–9:15 PM</td>
<td>Foundation of the NLA Event</td>
<td></td>
</tr>
</tbody>
</table>

### Sunday, March 20, 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00–7:50 AM</td>
<td>Breakfast</td>
<td></td>
</tr>
</tbody>
</table>

### Session VI: Update on Lipid Management in Special Populations

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:50–8:00 AM</td>
<td>Housekeeping Notes &amp; ARS Questions for Session VI</td>
<td></td>
</tr>
<tr>
<td>8:00–8:30 AM</td>
<td>Management of Dyslipidemia in Women Throughout the Lifespan</td>
<td>Pamela B. Morris, MD, FNLA*</td>
</tr>
<tr>
<td>8:30–9:00 AM</td>
<td>Lipid Management to Reduce ASCVD Risk in the Elderly: What is the Evidence?</td>
<td>Joyce L. Ross, MSN, CRNP, CLS, FNLA</td>
</tr>
<tr>
<td>9:00–9:30 AM</td>
<td>Evidence-Based Recommendations for Improving Adherence to Lipid Medication</td>
<td>Lynne T. Braun, PhD, CNP, CLS, FNLA</td>
</tr>
<tr>
<td>9:30–10:00 AM</td>
<td>ARS Questions and Q&amp;A Panel</td>
<td></td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>
PROGRAM PLANNERS

Harold E. Bays, MD, FNLA*†+
President, Southeast Lipid Association
Medical Director / President
Louisville Metabolic and Atherosclerotic Research Center
Louisville, KY

P. Barton Duell, MD
President, Pacific Lipid Association
Director, Lipid Disorder Clinic
Director, Lipid-Atherosclerosis Laboratory
Oregon Health & Science University
Portland, OR

Anne C. Goldberg, MD, FACP, FNLA*†+
President, Foundation of the NLA
Associate Professor of Medicine
Washington University School of Medicine
St. Louis, MO

Antonio M. Gotto, Jr., MD, DPhil, FNLA*
Dean Emeritus & Co-Chairman Board of Overseers
Professor
Lewis Thomas University
Weill Cornell Medical College
New York, NY

Linda C. Hemphill, MD, FNLA*†
President, Northeast Lipid Association
Instructor in Medicine
Harvard Medical School
Assistant Physician in Medicine
Massachusetts General Hospital
Boston, MA

Terry A. Jacobson, MD, FNLA*†
Immediate–Past President, National Lipid Association
Director, Office of Health Promotion and Disease Prevention
Professor of Medicine
Emory University
Atlanta, GA

Carl E. Orringer, MD, FACC, FNLA**
President, National Lipid Association
Associate Professor of Medicine
University of Miami School of Medicine
Miami, FL

Joseph J. Saseen, PharmD, CLS, FNLA°
Professor
Clinical Pharmacy and Family Medicine
University of Colorado Denver
Anschutz Medical Campus
Aurora, CO

Geeta Sikand, MA, RDN, CLS, FNLA, FAND
Associate Clinical Professor of Medicine: Cardiology
University of California Irvine School of Medicine
Director of Nutrition, University of California Irvine Preventive Cardiology Program
Irvine, CA

James A. Underberg, MD, MS, FNLA*†°
Treasurer, National Lipid Association
Clinical Assistant Professor of Medicine
NYU School of Medicine & NYU Center for Prevention of Cardiovascular Disease
Director, Bellevue Hospital Lipid Clinic
New York, NY

Kaye-Eileen Willard, MD, FNLA*
President, Midwest Lipid Association
Chief of Department of Medicine
Medical Director, Chronic Disease Management
Wheaton Franciscan Healthcare, All Saints Racine, WI

* Diplomate, American Board of Clinical Lipidology
† Clinical Lipid Update Program Faculty
° Lipid Academy Faculty
+ Masters in Lipidology Faculty

The NLA invites speakers and guests to provide scientific medical opinion, which do not necessarily reflect the policy of the NLA. The schedule and faculty are subject to change.
PROGRAM FACULTY

CLINICAL LIPID UPDATE FACULTY

Jane F. Barlow, MD, MPH, MBA
Associate Chief Medical Officer
CVS Health
Scottsdale, AZ

Lynne T. Braun, PhD, CNP, CLS, FNLA
Professor of Nursing and Nurse Practitioner
Rush University Medical Center
Chicago, IL

David R. Jacobs, PhD
Professor, Epidemiology and Community Health
Division of Epidemiology and Community Health
University of Minnesota
Minneapolis, MN

John M. Jakicic, PhD
Professor and Chair
Department of Health and Physical Activity
Director, Physical Activity and Weight Management Research Center
University of Pittsburgh
Pittsburgh, PA

Penny M. Kris-Etherton, PhD, RD, CLS, FNLA
Distinguished Professor of Nutrition
Pennsylvania State University
University Park, PA

Ralph La Forge, MSc, CLS, FNLA
Clinical Exercise Physiologist
Durham, NC

Kevin C. Maki, PhD, CLS, FNLA*
Chief Science Officer
Provident Clinical Research & Consulting
Glen Ellyn, IL

Seth S. Martin, MD, MHS, FACC
Assistant Professor of Medicine
Associate Director, Lipid Clinic
Ciccarone Prevention Center
Johns Hopkins University School of Medicine
Division of Cardiology
Baltimore, MD

Andrew Mente, PhD
Associate Professor
Department of Clinical Epidemiology and Biostatistics
McMaster University
Population Health Research Institute
Hamilton Health Sciences
Hamilton, Ontario, Canada

Kathryn J. Moore, PhD
Jean and David Blechman Professor of Cardiology
Department of Medicine
New York University School of Medicine
New York, NY

Pamela B. Morris, MD, FNLA*
Director, Preventive Cardiology
Co-Director, Women’s Heart Care
Medical University of South Carolina
Charleston, SC

Steve E. Nissen, MD, MACC
Chairman, Department of Cardiovascular Medicine
Cleveland Clinic
Professor of Medicine
Cleveland Clinic Lerner School of Medicine
Cleveland, OH

Joyce L. Ross, MSN, ANP, CLS, CRNP, FPCNA, FNLA
President-Elect, National Lipid Association
Consultative Education Specialist, Cardiovascular Risk Intervention
University of Pennsylvania Health System - Retired
Philadelphia, PA

Nathan O. Stitziel, MD, PhD
Assistant Professor of Medicine and Genetics
Director, Center for Cardiovascular Genetics
Assistant Director, McDonnell Genome Institute
Washington University School of Medicine
St. Louis, MO

Joseph L. Witztum, MD
Distinguished Professor of Medicine
University California, San Diego
La Jolla, CA

LIPID ACADEMY FACULTY

Lori Alexander, MSHS, RD, CCRC, CLS, FNLA
Immediate–Past President, Southeast Lipid Association
Site Manager
St. Johns Center for Clinical Research
Ponte Vedra, FL

Michael J. Bloch, MD, FACP, FASH, FVM, FNLA*
Associate Professor
Department of Medicine, University of Nevada School of Medicine
Medical Director
Vascular Care, Renown Institute for Health and Vascular Health
Renown Regional Medical Center
Reno, NV

MASTERS OF LIPIDOLOGY FACULTY

Vera A. Bittner, MD, MSPH, FNLA*
Professor of Medicine
Section Head, Preventive Cardiology
University of Alabama at Birmingham
Birmingham, AL

Alan S. Brown, MD, FACC, FAHA, FNLA*
Interventional Cardiologist
Midwest Heart Specialists
Clinical Associate Professor
Loyola University
Maywood, IL

CODING COURSE FACULTY

Emily Hill, PA
President
Hill & Associates
Wilmington, NC
PCSK9 Inhibitors: Do the FDA-Approved Indications Mandate Lipid Goals?

Jane F. Barlow, MD, MPH, MBA
Associate Chief Medical Officer
CVS Health
Scottsdale, AZ

Friday, March 18, 2016
4:00–4:30 PM
General Session Room

This presentation will highlight the need to achieve consensus around management strategies for patients with hyperlipidemia. The first two therapies in the new class of drugs — PCSK9 inhibitors — recently received FDA approval. These injectables are highly effective in lowering cholesterol levels. But at a price tag of $14,000 or more per patient each year the costs will add up quickly and further strain limited health care system budgets.

Current guidelines could inadvertently limit the ability to manage utilization of these high-cost agents. The guidelines do not offer sufficient clarity to prescribers to identify appropriate use of PCSK9 inhibitors relative to other treatments, many of which are generic medications available at a much lower cost. This session will explore the role of guidelines in ensuring appropriate access to the drugs, steps taken to manage utilization based on guidelines, and the important role of lipid goals in this process.

A thoughtful, disciplined, and clinically sound approach to PCSK9 inhibitors and other high-cost medications will help provide patients access to the drugs they need, while lessening the cost burden on the health care system.

PCSK9 Inhibitors: Practical Aspects of Their Use in Patients with FH

James A. Underberg, MD, MS, FNLA
Clinical Assistant Professor of Medicine NYU School of Medicine
NYU Center for Prevention of Cardiovascular Disease
Director, Bellevue Hospital Lipid Clinic
New York, NY
Diplomate, American Board of Clinical Lipidology

Saturday, March 19, 2016
4:45–5:15 PM
General Session Room

With the recent release of two new agents for LDL-Cholesterol lowering that inhibit PCSK9, practitioners now have another option for the management of patients with atherosclerotic cardiovascular disease (ASCVD) and familial hypercholesterolemia (FH). The practical use of alirocumab and evolocumab for the treatment of patients with FH will be reviewed with a focus on current diagnostic criteria for both homozygous and heterozygous FH.

An overview of MEDPED, Simon Broome, and Dutch Lipid Clinic Network criteria will be provided, along with newer recommendations that attempt to harmonize and simplify these tools. In addition, utilization of case presentations will demonstrate how these agents should be inserted into current treatment and management algorithms.

This session will also review current knowledge regarding FH and ASCVD risk, along with timing and aggressiveness of therapy and the possible role that PSCK9 inhibitors may play in changing the way we manage patients with FH.
SPECIAL EVENTS

FOUNDATION EVENT
The Dinner Detective
Saturday, March 19, 2016
6:30–9:15 PM
$85 per person

Join the Foundation of the National Lipid Association on the evening of March 19, 2016, for a murder mystery comedy dinner show, designed just for our group. Laugh, interact, and attempt to solve the mystery with colleagues during the show. The killer will be hiding somewhere in the room, and you may find yourself as the prime suspect! Hor d’oeuvres, dinner, and dessert will accompany the fun-filled evening.

A portion of the ticket price will be donated to the Foundation. Cash bar will be available.

The event is in walking distance from the Omni Hotel.

Welcome Reception
Friday, March 18, 2016
6:00–7:00 PM
Exhibit Hall

Join your fellow colleagues and the exhibitors for an opening reception on Friday evening in the exhibit hall. Visit with more than 15 exhibiting companies and mingle, while enjoying tasty hors d’oeuvres and cocktails.

This reception is included in the registration; guests with an exhibit hall pass are also welcome.

New Member Breakfast
Saturday, March 19, 2016
7:00–7:50 AM
Exhibit Hall – Reserved Tables

Enjoy breakfast on Saturday morning with new and active members in the organization. Would you like to learn how the NLA can benefit your career? This is a wonderful opportunity to ask leaders in the NLA questions you may have about their experience in the association and how they have benefited from the educational opportunities and the relationships created. Create new connections with other members that will enrich your experience as an NLA member and last a lifetime.
Omni San Diego Hotel
675 L Street
San Diego, CA 92101

Meeting Room Rate: $229/night ++
Room Reservation Cut-Off Date: February 18, 2016
For reservations call 1-800-THE-OMNI and ask for the National Lipid Association room rate. Reserve your room early for a discounted rate.

The newly renovated four-star Omni San Diego Hotel is located in the heart of the historic Gaslamp Quarter. Omni San Diego Hotel puts you close to the city’s top sites and attractions. Omni Hotels & Resorts makes every stay memorable, unique and authentic to the local culture by taking personal service to heart. Each Omni property blends seamlessly into the local culture while featuring four-diamond services, signature restaurants, WiFi connectivity and unique wellness options.

Travel Information:
Book your airfare on Delta and receive up to 5% off of your flight to San Diego. Book your flight on delta.com and enter NMMQJ in the "offer" code box when searching for your flight. Discount applicable for travel to and from San Diego between March 15–20, 2016.

San Diego Zoo
The San Diego Zoo has been voted the number one zoo in the world. The 100-acre zoo is home to over 3,700 rare and endangered animals representing more than 650 species and subspecies, and a prominent botanical collection with more than 700,000 exotic plants. It is located just north of downtown San Diego in Balboa Park.

USS Midway Museum
Imagine experiencing life at sea aboard one of America’s longest-serving aircraft carriers. Visitors to the USS Midway Museum enter a floating city at sea and walk in the footsteps of 225,000 Midway sailors who served our country and upheld the American ideals of strength, freedom and peace.

View more local attractions on lipid.org/springclu or sandiego.org.
Friday, March 18 | 3:40–6:00 PM
Saturday, March 19 | 8:00 AM–6:15 PM
Sunday, March 20 | 8:00–10:00 AM
$545 NLA Members, $895 Non-members, $75 Trainees

Target Audience
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses and registered dietitians with an interest in lipid management.

Type of Activity
Live Activity
Knowledge

Educational Objectives
At the conclusion of this activity, registered nurses and nurse practitioners should be able to provide appropriate counsel for patients and their families.

At the conclusion of this activity, all participants should be able to:

Session I: PCSK9 Inhibition: A New Paradigm in LDL-C Reduction
• Analyze how new therapies may impact current guidelines
• Describe the role of PCSK9 inhibitors in patients with elevated LDL-C and its impact on apheresis
• Assess the data on safety and efficacy of therapies that target proprotein convertase subtilisin/kexin type 9 (PCSK9) to provide additional lipid lowering benefits

Session II: Keeping Up to Date in Clinical Lipidology
• Discuss the potential role of health information technologies in optimizing lipid management
• Review current literature of particular importance to the practice and science of clinical lipidology
• Describe the efficacy, safety, and mechanisms of action of novel lipid-targeted pharmacotherapies

Session III: Application of Innovative Diagnostic Techniques to the Practice of Clinical Lipidology
• Evaluate the role of Micro RNAs in the regulation of lipid metabolism
• Review the use of newer imaging modalities for screening and preventing coronary artery disease
• Evaluate the use of genetics to modify lipid therapies in patients with hypertriglyceridemia

Session IV: Debates in Lifestyle Therapy
• Examine evidence around Current Dietary Recommendations for Heart Health
• Compare and contrast the impact of saturated fats and diet on their lipid lowering effects
• Review the role of physical activity on dyslipidemia and cardiovascular risk

Session V: New Advances in Treatment of Familial Hypercholesterolemia
• Describe the current and future technologies available for genetic FH screening
• Identify the potential roles that PCSK9 Inhibitors may play in management of Patients with FH
• Discuss treatment strategies for familial hypercholesterolemia via case study presentations

Session VI: Update on Lipid Management in Special Populations
• Implement appropriate treatment strategies for women with dyslipidemia
• Assess the evidence evaluating dyslipidemia pharmacology in elderly
• Review the scientific research relating to adherence to lipid-lowering therapies and the impact on treatment decisions

Register early and save at lipid.org/springclu
Spring Clinical Lipid Update

CE credit provided by the National Lipid Association

Physicians
The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Lipid Association designates this live activity for a maximum of 12.75 AHA PRA Category 1 Credits™. Physicians should claim only credit commensurate with their participation in this activity.

Pharmacists
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Session I - Universal Activity Number 0809-9999-16-026-L01-F (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.25 contact hour(s) (2.25 CEUs) of the Accreditation Council for Pharmacy Education

Session II - Universal Activity Number 0809-9999-16-027-L01-F (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hour(s) (2.0 CEUs) of the Accreditation Council for Pharmacy Education

Session III - Universal Activity Number 0809-9999-16-028-L01-F (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.25 contact hour(s) (2.25 CEUs) of the Accreditation Council for Pharmacy Education

Session IV - Universal Activity Number 0809-9999-16-029-L01-F (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.25 contact hour(s) (2.25 CEUs) of the Accreditation Council for Pharmacy Education

Session V - Universal Activity Number 0809-9999-16-030-L01-F (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.25 contact hour(s) (2.25 CEUs) of the Accreditation Council for Pharmacy Education

Session VI - Universal Activity Number 0809-9999-16-031-L01-F (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.25 contact hour(s) (2.25 CEUs) of the Accreditation Council for Pharmacy Education

Nursing
This educational activity for 12.5 contact hours is provided by the Postgraduate Institute for Medicine.

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Session 1-2 credits, Session II-2 credits, Session III-2 credits, Session IV-2 credits, Session V-2 credits, Session VI-2 credits.

California Board of Registered Nursing
Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 12.5 contact hours.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

Criteria for Success:
Statements of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.lipid.org/cme for Pharmacists. Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Disclosure Statement:
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity.

NLA planners and reviewers have no relevant financial relationships to disclose.

Commercial Support:
Financial notification of commercial support will be provided in the activity syllabus.

NLA Lipid Academy

Target Audience
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, advance practice registered nurses, registered nurses, nurse practitioners and registered dietitians with an interest in lipid management.

Type of Activity
Application

Learning Objectives
At the conclusion of this activity, participants should be able to:• Describe the functions and sources of cholesterol and triglycerides including the role of lipoproteins in atherosclerosis• Explain the pathophysiology of atherosclerosis• Identify the role of inflammation in atherosclerosis• Discuss clinical trials including their role in lipid and lipoprotein treatment in cardiovascular prevention• Review the clinical trials of lipid-altering drug therapies used in cardiovascular disease prevention• Apply basic principles of statistics to enhance understanding of clinical trials related to lipid management• Compare and contrast the effectiveness of available risk assessment instruments and markers in predicting CV risk in all population groups• Identify primary and secondary causes of dyslipidemias• Recognize the role of drug therapy in the management of dyslipidemia• Review the mechanisms of action, pharmacokinetics, and efficacy of available FDA approved drugs for the management of lipid disorders• Assess the side effects of lipid-altering drugs to encourage their safe use in cardiovascular disease prevention• Describe the appropriate use of lipid-altering drugs in special populations• Describe effective diet and lifestyle strategies for long-term obesity and dyslipidemia management• Describe the association of specific dietary patterns such as increased sodium and sugar intake, and the increased risk for cardiovascular disease associated morbidity and mortality• Compose a clinical care plan for reducing risk of CVD in patients with dyslipidemia• Analyze case studies in lipid management to improve treatment and prevention of cardiovascular disease• Analyze lipid cases for health professionals seeing patients with complex disorders• Identify the management of dyslipidemia in special populations based on gender, culture, and disease variables

For Registered Nurses and Nurse Practitioners only
Provide appropriate care and counsel for patients and their families

CE credit provided by Postgraduate Institute for Medicine

Pharmacists
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 12.6 contact hours.

CE credit provided by Postgraduate Institute for Medicine

Physicians
The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Lipid Association designates this live activity for a maximum of 12.75 AHA PRA Category 1 Credits™. Physicians should claim only credit commensurate with their participation in the activity.

Physician Assistants
NCCPA accepts AHA PRA Category 1 Credits™ from organizations accredited by ACCME.

Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 12 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #N1002.

American Academy of Family Physicians
Application for CME credit has been filed with the American Academy of Family Physicians. Determination of credit is pending.

CE credit provided by Postgraduate Institute for Medicine

Pharmacists
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 12.6 contact hours.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

ACCREDITATION

Register early and save at lipid.org/springclu
Masters in Lipidology Course

Target Audience
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, advanced practice registered nurses, nurse practitioners and registered dietitians with an interest in lipid management.

Type of Activity
Knowledge, Application

Learning Objectives:
At the conclusion of this activity, participants should be able to:
• Explain lipoprotein metabolism and its role in the pathogenesis of atherosclerosis
• Describe genetic disorders affecting lipoprotein metabolism
• Describe the vascular biology and pathophysiology of atherosclerosis
• Apply basic principles of evidence based medicine to enhance understanding of clinical trial results, methods for cardiovascular risk stratification, and applying new research into practice
• Explain clinical practice guidelines, the different types of evidence used to make clinical guidelines, and the role of clinical judgment in applying guidelines to practice
• Outline current issues and approaches to global cardiovascular risk assessment
• Assess traditional and emerging biomarkers for the prevention and treatment of atherosclerotic cardiovascular disease
• Review the role of subclinical atherosclerosis testing (magnetic resonance angiography) in cardiovascular disease risk assessment and management
• Identify the evidence base that supports current dietary recommendations for heart health
• Describe effective diet and lifestyle interventions for weight management and strategies for the management of dyslipidemia and cardiovascular risk
• Identify how general dietary patterns and specific macronutrients (fats, carbohydrates) affect coronary heart disease and lipid levels
• Explain how obesity and subcutaneous fat contribute to the metabolic syndrome and diabetes mellitus
• Identify management strategies for the cardiometabolic risk factors of the metabolic syndrome
• Review the mechanism of action, pharmacokinetics, and efficacy of approved drugs for the management of lipid disorders
• Assess the side effects of lipid-lowering drugs to encourage their safe use in cardiovascular disease prevention
• Review clinical trials of lipid-lowering drug therapies used in cardiovascular disease prevention
• Describe combination therapies for the management of complex lipids disorders and residual risk
• Manage complex dyslipidemia and dysglycemia in special populations

For Registered Nurses and Nurse Practitioners only
Provide appropriate care and counsel for patients and their families

NLA Coding Course

Target Audience
This program has been designed for physicians with a basic understanding of CPT and ICD-10.

Type of Activity
Live

Learning Objectives:
At the conclusion of this activity, the attendee can expect to be able to:
• Implement Evaluation and Management Code guidelines and documentation requirements to the clinical practice
• Apply screening and preventive codes and services into lipid and cardiometabolic risk reduction programs
• Recognize ICD-10-CM Changes important to Lipid and Cardiometabolic Risk Reduction Programs

CME credit provided by the National Lipid Association

Physicians
The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The National Lipid Association designates this live activity for a maximum of 16.00 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by ACCME.

Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 16 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #902

American Academy of Family Physicians
Application for CME credit has been filed with the American Academy of Family Physicians. Determination of credit is pending.

CE Credit provided by Postgraduate Institute for Medicine

Pharmacists
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Day 1 Morning Session - Universal Activity Number - 0829-9999-16-044-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEU(s) of the Accreditation Council for Pharmacy Education.

Day 1 Afternoon Session - Universal Activity Number - 0829-9999-16-045-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 4.25 contact hours (0.425 CEU(s) of the Accreditation Council for Pharmacy Education.

Day 2 Morning Session - Universal Activity Number - 0829-9999-16-046-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 4.75 contact hours (0.475 CEU(s) of the Accreditation Council for Pharmacy Education.

Day 2 Afternoon Session - Universal Activity Number - 0829-9999-16-047-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 2.5 contact hours (0.25 CEU(s) of the Accreditation Council for Pharmacy Education.

Nursing
This educational activity for 15.9 contact hours is provided by Postgraduate Institute for Medicine.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Day 1 Morning Session- 3.8 credits, Day 1 Afternoon Session- 5.0 credits, Day 2 Morning Session- 4.6 credits, Day 2 Afternoon Session- 2.5 credits.

California Board of Registered Nursing
Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 15.9 contact hours.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

Register early and save at lipid.org/springclu
BEFORE YOU GO

New in 2016: Mobile App

The National Lipid Association will be providing an app with onsite updates and educational content for attendees. Please check the website for information coming soon about how to download the app in preparation for the meeting. Make sure to bring your device because we will not be providing a printed syllabus. The app is compatible with laptops, tablets, and mobile devices.

Your Registration Includes:

• Access to educational sessions of CLU
• Welcome Reception hors d’oeuvres and cocktails
• Breakfast on Saturday and Sunday
• Lunch on Saturday
• Meeting bag

NLA Members Save up to $400

Not yet a member? Join the National Lipid Association today and take advantage of the member discounts and save up to $400. For only $150, you can enjoy a multitude of member benefits, including discounts on other educational resources. Learn more about NLA membership by visiting lipid.org/join.

NLA’s Trainee Travel Grant Program

Are you a fellow-in-training who has a focus in lipid management? Learn about the NLA’s Trainee Travel Grant Program! Fifteen grants are available for the NLA Lipid Academy Courses, each including a $500 travel grant and complimentary attendance for Lipid Academy — plus NLA membership for lipid focused fellows-in-training is always complimentary. Due to the popularity of this program, please act quickly. For more information, contact Amanda East at aeast@lipid.org. For additional trainee opportunities, visit lipid.org/education/fellows.

Get Engaged

Be part of the conversation and get the latest news and announcements from the Spring CLU. Follow NLA on Twitter, Instagram, LinkedIn, and Facebook. Use hashtag #NLASanDiego when posting about the meeting.

Register early and save at lipid.org/springclus
2016 Clinical Lipid Update • March 18–20, 2016 • Omni Hotel San Diego • San Diego, CA.

First Name ___________________________ Middle Initial ___________________________ Last Name ___________________________

Mailing Address
________________________________________________________

City ___________________________ State or Province ___________________________ Zip ___________________________ Country ___________________________

Phone ___________________________ Emergency Contact/Phone ___________________________ Cell Phone* ___________________________

Email ___________________________

Check all that apply: □ MD/DO/PhD □ RN □ NP □ PA □ RPH □ PharmD □ RD □ Other ___________________________

Guest name(s), if attending meeting: ___________________________________________

The following are prices for the 2016 Clinical Lipid Update and related events. 

<table>
<thead>
<tr>
<th>Event Description</th>
<th>NLA Member Early Bird Rate</th>
<th>NLA Member Discounted Rate</th>
<th>Non-member Rate</th>
<th>Trainee Rate†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Lipid Update March 18–20, 2016</td>
<td>$495</td>
<td>$545</td>
<td>$895</td>
<td>$75</td>
</tr>
<tr>
<td>Professional Development</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Masters in Lipidology Course* March 17–18, 2016</td>
<td>$750</td>
<td>$750</td>
<td>$1250</td>
<td>$395</td>
</tr>
<tr>
<td>Lipid Academy March 17–18, 2016</td>
<td>$550</td>
<td>$550</td>
<td>$950</td>
<td>$0</td>
</tr>
<tr>
<td>NLA Coding Course March 18, 2016</td>
<td>$200</td>
<td>$200</td>
<td>$200</td>
<td>$200</td>
</tr>
</tbody>
</table>

Registration Fees Total $_______ $_______ $_______ $_______

Admission badges are limited and non-refundable. 

ADA Compliance: Contact the National Lipid Association at 904-998-0854 for additional accommodations if necessary.

Special Events and Guest Fees

Foundation of the NLA Event $85 X____ = $_______

Exhibit Hall Pass-Guest(s) $150 X____ = $_______

Registration Discount Disclaimer: Discount codes cannot be retroactively applied to existing meeting registrations. The meeting discount codes are applicable to new registrants only.

3 Easy Ways To Register

Mail
National Lipid Association
6816 Southpoint Parkway, Suite 1000
Jacksonville, FL 32216

Fax
NLA at 904-998-0855
Fax with credit card number and signature

Online
lipid.org/springclu

*By providing your cellular phone number, you are enrolling into the NLA’s text alert system. The NLA may send you SMS and MMS text messages, specifically related to the event for which you are registering, between the dates of March 18–20, 2016. You will be able to reply STOP at any time to opt out of the system. Standard text messaging rates may apply.

Registration: Registration and payment must be received no later than February 26, 2016. After this date, meeting materials and name badge cannot be guaranteed.

Cancellation: Telephone cancellations will not be accepted. A written notice of cancellation must be received no later than February 26, 2016. This includes social events and guest fees. There will be a $100 fee for all cancellations.

Special needs: __________________________________________________________

ADA Compliance: Attendees who need additional reasonable accommodations or who have special needs should contact the NLA at 904.998.0854.

*Master’s Course: To purchase the NLA-SAPs please go to: lipid.org/education/nlasap.

†Trainee Rate: Available for those individuals actively enrolled in a graduate or postgraduate training program for the treatment or investigation of lipid disorders and in pursuit of full credentialing in their specialized area of medical study. A letter from the program director or the school registrar must accompany the application.

Your card payment information is secure. Make checks payable to the NLA. 

Make checks payable to the NLA

Credit Card # ___________________________ Exp. Date ___________________________

Signature ___________________________

Name on Card ___________________________

Register early and save at lipid.org/springclu
Airline Discount

Book your airfare on Delta and receive up to 5% off of your flight to San Diego. Book your flight on delta.com and enter NMMQJ in the “offer” code box when searching for your flight. Discount applicable for travel to and from San Diego between March 15–20, 2016.